Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)
Close on Nov 17, 2026Market cap $287.64MP/E –Yield –
Emergent BioSolutions pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Emergent BioSolutions's pe ratio was 8.8× on Apr 30, 2026, against 12.3× a year earlier. Over the last 5 years it ranged from 3.4× to 787.0×, with a median of 16.9×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 8.8× | −0.7 |
| 2025 | Dec 31, 2025 | 9.5× | −9.3 |
| 2023 | Jan 31, 2023 | 18.8× | +2.0 |
| 2022 | Dec 30, 2022 | 16.9× | +5.8 |
| 2021 | Dec 31, 2021 | 11.1× | −17.6 |
| 2020 | Dec 31, 2020 | 28.7× | −742.0 |
| 2019 | Dec 31, 2019 | 770.7× | +740.5 |
| 2018 | Dec 31, 2018 | 30.2× | +4.3 |
| 2017 | Dec 29, 2017 | 26.0× | −7.2 |
| 2016 | Dec 30, 2016 | 33.2× | −0.2 |
| 2015 | Dec 31, 2015 | 33.3× | −23.4 |
| 2014 | Dec 31, 2014 | 56.7× | +21.4 |
| 2013 | Dec 31, 2013 | 35.4× | +16.3 |
| 2012 | Dec 31, 2012 | 19.1× | −9.9 |
| 2011 | Dec 30, 2011 | 29.0× | +5.3 |
| 2010 | Dec 31, 2010 | 23.7× | – |
See a number that looks wrong?